Specialty Biopharma
- Pipeline
- Biologics
- Biosimilars
Listening to our customers to solve unmet needs, create accessibility and bring innovative technology platforms that impact patient care!
We are committed to help solve unmet needs by being focused within the biopharma industry on products that make a difference. Our dedication to this goal is demonstrated through our development pipeline and initiatives, including our recently announced acquisition to commercialize an orphan drug within the rare disease space of sarcoidosis.
The creation of a sustainable and competitive marketplace for biosimilars has the potential to improve patient access, increase treatment options, and generate savings and efficiencies for healthcare systems. Strategic partnerships and internal capabilities will see Meitheal have several biosimilars in our pipeline by end of 2023.
Breakthrough technologies are bringing treatments to patients faster. Meitheal is working with strategic partners on developing products and platforms that will impact patient care.
To meet our customers needs, Meitheal is partnering externally and developing internally biosimilars and biologics that will impact patient care!
Biologics
Recently announced acquisition to commercialize orphan drug within the rare disease space of sarcoidosis
Biosimilars
Strategic partnerships and internal capabilities will see Meitheal have several biosimilars in our pipeline by end of 2023
Potential Market Opportunity
Our Pipeline
Biologics
| Drug Name | Therapeutic Area | Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submission |
|---|---|---|---|---|---|---|---|---|
| XTMAB-16 | Sarcoidosis | Biologic | ||||||
Biosimilars
| Drug Name | Therapeutic Area | Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submission |
|---|---|---|---|---|---|---|---|---|
| MAB-22 | Oncology | Biosimilar | ||||||
| Insulin Aspart | Diabetes | Biosimilar | ||||||
| Insulin Glargine | Diabetes | Biosimilar | ||||||
| Insulin Lispro | Diabetes | Biosimilar | ||||||
You might also be interested
The brands mentioned here are the trademarks of their respective owners.